TXMD Earnings & Financial Statements
TherapeuticsMD, Inc.
$1.80
-$0.05(-2.70%)
--
Overall
--
Value
--
Tech
--
Quality
Market Cap
--
Volume
15.70K
52W Range
$1.08 - $2.95
Target Price
--
TXMD earnings and financial statements: TherapeuticsMD, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TXMD Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $3.02M | $1.76M | $1.30M | $69.96M | $2.57M |
| Cost of revenue | - | - | - | $1.40M | $1.40M |
| Operating income | -$4.39M | -$6.11M | -$8.52M | $10.66M | -$79.58M |
| EBITDA | $540.0K | -$1.06M | -$6.65M | $11.86M | -$78.84M |
| Net income | -$569.0K | -$2.18M | -$10.28M | $112.00M | -$172.41M |
| EPS (diluted) | $-0.05 | $-0.19 | $-0.98 | $11.95 | $-21.50 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $37.66M | $38.82M | $43.31M | $90.46M | $169.47M |
| Total liabilities | $10.78M | $11.45M | $14.02M | $55.31M | $263.09M |
| Shareholders’ equity | $26.88M | $27.37M | $29.29M | $35.14M | -$93.62M |
| Cash and equivalents | $7.48M | $5.06M | $4.33M | $38.07M | $64.91M |
| Long-term debt | $5.12M | $5.54M | $6.53M | $7.37M | $8.06M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $2.45M | $1.17M | -$23.08M | $9.36M | -$55.13M |
| Capital expenditure | - | - | - | -$355.0K | -$2.22M |
| Free cash flow | $2.45M | $1.17M | -$23.08M | $9.00M | -$57.36M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TXMD | $1.80 | -2.7% | 15.70K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |